Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib in RET-altered thyroid cancer, NSCLC, and other advanced solid tumors
NL-OMON56358Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pralsetinib in thyroid cancer, Medullary Thyroid Cancer (MTC), non-small cell lung cancer (NSCLC) and 1 more (8 arms), sponsored by Roche. Primary endpoints: Overall response rate and Safety and tolerability. Started Mar 2017; status: recruiting.
02
Drugs
pralsetinib
03
Conditions
thyroid cancerMedullary Thyroid Cancer (MTC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON56358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56358.